PFE - Alnylam: Suing Moderna Pfizer Over LNP Technology. There May Be Method In This Madness

• Alnylam is an RNA-interference drug developer that was founded in 2002 and joined the Nasdaq in 2004.
• Alnylam Pharma has been studying Lipid Nanoparticle technology intensively for more than a decade and alleges it once shared its technology with Moderna in 2014.
• Alnylam is alleging Moderna used its patented LNP technology in its COVID vaccine, and is also suing Pfizer for the same reason.
• Alnylam may have a point - and LNP technology is a critical component of the Spikevax and Comirnaty vaccines which will likely have earned >$100bn by FY22.
• Could Alnylam win a court battle against Moderna & Pfizer, earning a payout in the billions, whilst striking a major blow for its RNAi over MRNA in other disease types? It may sound far fetched but equally it may have made ALNY shares a bargain at current price.

For further details see: